Want to see EMBC full AI Analyst Report?
EMBC Stock Chart & Stats
$9.78
$0.16(0.83%)
At close: 4:00 PM EST
$9.78
$0.16(0.83%)
Day’s Range― - ―
52-Week Range$2.77 - $15.55
Previous CloseN/A
Volume119.84K
Average Volume (3M)2.22M
Market Cap
$192.22M
Enterprise Value$1.36B
Total Cash (Recent Filing)$184.90M
Total Debt (Recent Filing)$1.36B
Price to Earnings (P/E)1.7
Beta0.61
Next Earnings
Aug 07, 2026EPS Estimate
0.27Next Dividend Ex-DateN/A
Dividend Yield5.03%
Share Statistics
EPS (TTM)1.91
Shares Outstanding59,327,680
10 Day Avg. Volume1,613,392
30 Day Avg. Volume2,215,289
Financial Highlights & Ratios
PEG Ratio0.42
Price to Book (P/B)-1.26
Price to Sales (P/S)0.76
P/FCF Ratio4.51
Enterprise Value/Market Cap7.05
Enterprise Value/Revenue1.30
Enterprise Value/Gross Profit2.08
Enterprise Value/Ebitda4.21
Forecast
1Y Price Target
$4.00Price Target Upside-59.10% Downside
Rating ConsensusModerate Sell
Number of Analyst Covering3
EPS Forecast (FY)1.57
Revenue Forecast (FY)$1.02B
Bulls Say, Bears Say
Bulls Say
Consumable Recurring RevenueEmbecta’s core business is consumables—disposable pen needles and syringes—sold to pharmacies, distributors and healthcare providers. That recurring, replenishment-driven demand creates durable revenue streams tied to chronic diabetes care, supporting predictable near-term volumes and long-term cash inflows.
Strong Recent Free Cash FlowRecent TTM cash generation is robust, with FCF near $205M, enabling debt paydowns and funding strategic actions without immediate equity raises. Sustained cash conversion provides financial flexibility for capex, integration of acquisitions and targeted deleveraging over the 2–6 month horizon, though consistency should be monitored.
Strategic Diversification (Owen Mumford & GLP‑1)The Owen Mumford acquisition and expanding GLP‑1 B2B partnerships materially broaden product exposure beyond pen needles, adding an auto‑injector platform and new pharma customers. This reduces single-category dependency, supports geographic expansion and creates medium-term revenue diversification and higher addressable market potential.
Bears Say
High Leverage And Negative EquityEmbecta’s capital structure is strained: large gross debt and negative shareholders’ equity limit flexibility for M&A, reinvestment, or buffering further operational shocks. Even with current covenant headroom, refinancing risk and higher interest/credit costs could impair long-term strategic options and constrain growth investments.
Concentrated U.S. Pen‑needle Share LossA concentrated customer-driven share loss in U.S. pen needles exposed structural distribution and competitive vulnerability. Reliance on a small set of large accounts creates revenue volatility; persistent channel shifts and customer mix changes can maintain lower volumes and pressure margins for multiple quarters.
Material Guidance And Margin CutsSignificant downward revisions to revenue, margins and FCF indicate structural headwinds (share loss, volume softness, pricing/inventory shifts). Lower margins and weaker cash outlook reduce reinvestment capacity, prompted a dividend cut, and may necessitate further cost actions, constraining durable earnings recovery.
Embecta Corporation News
EMBC FAQ
What was Embecta Corporation’s price range in the past 12 months?
Embecta Corporation lowest stock price was $2.77 and its highest was $15.55 in the past 12 months.
What is Embecta Corporation’s market cap?
Embecta Corporation’s market cap is $192.22M.
When is Embecta Corporation’s upcoming earnings report date?
Embecta Corporation’s upcoming earnings report date is Aug 07, 2026 which is in 26 days.
How were Embecta Corporation’s earnings last quarter?
Embecta Corporation released its earnings results on May 05, 2026. The company reported $0.27 earnings per share for the quarter, missing the consensus estimate of $0.417 by -$0.147.
Is Embecta Corporation overvalued?
According to Wall Street analysts Embecta Corporation’s price is currently Overvalued.
Does Embecta Corporation pay dividends?
Embecta Corporation pays a Quarterly dividend of $0.01 which represents an annual dividend yield of 5.03%. See more information on Embecta Corporation dividends here
What is Embecta Corporation’s EPS estimate?
Embecta Corporation’s EPS estimate is 0.27.
How many shares outstanding does Embecta Corporation have?
Embecta Corporation has 59,327,680 shares outstanding.
What happened to Embecta Corporation’s price movement after its last earnings report?
Embecta Corporation reported an EPS of $0.27 in its last earnings report, missing expectations of $0.417. Following the earnings report the stock price went down -57.835%.
Which hedge fund is a major shareholder of Embecta Corporation?
Currently, no hedge funds are holding shares in EMBC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Embecta Corporation Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Sell
Average Price Target:
$4.00 (-59.10% Downside)
$4.00 (-59.10% Downside)
Blogger Sentiment
Neutral
EMBC Sentiment 50%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 825.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 20.0%
Last 30 Days ▼ 20.0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-68.54%
12-Months-Change
Fundamentals
Return on Equity
-17.49%
Trailing 12-Months
Asset Growth
-8.11%
Trailing 12-Months
Company Description
Embecta Corporation
Embecta Corp. is a medical technology enterprise devoted to enhancing the quality of life and health outcomes for individuals living with diabetes. Its comprehensive product portfolio includes essential tools such as pen needles, syringes, and advanced safety devices. Additionally, the company provides innovative digital applications designed to support patients in effectively managing their condition. Embecta distributes its offerings primarily through a network of wholesalers and distributors, reaching markets both domestically within the United States and across the globe. Established in 1924, Embecta's headquarters are located in Parsippany, New Jersey. The company transitioned to an independent entity from Becton, Dickinson and Company on April 1, 2022.
EMBC Company Deck
EMBC Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Negative
The call presents meaningful strategic progress (Owen Mumford acquisition, GLP‑1 B2B traction, brand transition progress, debt repayment and a share buyback authorization) but was dominated by substantial near‑term operational and financial setbacks: large revenue declines (especially in the U.S. and pen needles), sharp margin and EPS guide cuts, a GAAP net loss in the quarter, and material reductions in free cash flow guidance. Management has initiated cost/organization reviews and highlighted actions underway, but the magnitude and persistence of the U.S. share loss and market volume softness create significant short‑term headwinds.View all EMBC earnings summariesEMBC Stock 12 Month Forecast
Average Price Target
$4.00
▼(-59.10% Downside)
Technical Analysis
―
Pacira Pharmaceuticals
―
SIGA Technologies
―
Collegium Pharmaceutical
―
Organogenesis Holdings
―
Ownership Overview
3.24% Insiders
29.04% Mutual Funds
0.65% Other Institutional Investors
52.54% Public Companies and
Individual Investors